MedTrace Logo

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections

NCT03406689 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2018-04-04

No results posted yet for this study

Summary

The analgestic efffect of Nepafenac 0.1% Eye Drops and Nepafenac 0.3% Eye Drops on pain related to intravitreal injections will be evalutated.

Pain perception will be assessed by the Short Form of the McGill Pain Questionnaire.

Conditions

Interventions

DRUG

Nepafenac 0.1% Oph Susp

One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.

DRUG

Nepafenac 0.3% Oph Susp

One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.

DRUG

Artificial tear

One drop Artificial Tears will be instilled 45' prior to the IVI.

Sponsors & Collaborators

  • University Hospital of Patras

    lead OTHER

Principal Investigators

  • Constantine Georgakopoulos, MD, PhD · Associate Professor of Ophthalmology, Medical School, University of Patras, Greece

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-02-28
Completion
2018-03-28

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03406689 on ClinicalTrials.gov